UnitedHealth Group Inc (UNH)

It has seen many problems this year, including missing earnings and lowering guidance. Insurance is tough to understand, especially when connected to Medicare.  Then again, the valuation fell and aging demographics are tailwinds. UNH is a turnaround story and will need time. It's weird that Buffett is investing in this, since he doesn't invest in turnarounds. Too many moving parts for him to study. He avoids healthcare.

On top of medical loss ratio issue, now being investigated by DOJ on billing practices. Suspects this will be like a WFC scenario -- clouds will hang over the name and will take a long time to clear. EPS revised down from $25 to $16, so who knows what they'll actually be by year's end.

Likes HMOs in general as a business that reprices YOY. If you're a very long-term investor and you want to take a stab, it's not going away anytime soon. But expect a bumpy ride for the next 1-6 quarters.

RFK Jr.'s crusade to cut health costs includes cutting vaccines, and that is a serious headwind. The result is that broad healthcare hasn't been this cheap in a long time and you can enter it now. People will still need therapies and get sick. Are better opportunities than UNH in healthcare.

Is -39% this year. The fact that Buffett is buying shares doesn't influence him. He needs to hear the company sell their story.

Buffett's very smart and can give you a reason to look at a stock. Catching a falling knife isn't his strategy. Turnaround will not be quick or smooth. He's avoided healthcare for the most part, owning just BSX.

He re-entered this, because the stock was moving up. Later, he realized it was because of Buffett buying it. The fundamentals alone are dead money. Expect it to hit $325 then pause. They won't resume growth till 2026.

He added more last week and today. The market wants momentum.

Dark clouds are concern about overstated revenues plus current regulatory environment. If you want to invest in something and look like a hero a year from now, you could take a very small percentage. Taking on risk if something else blows up. Can't see a basing pattern yet.

Stock's PE is cheap, but he sees negative earnings growth over next few years. Reports of hedge fund companies getting in is a positive. Very oversold.

Numbers are fantastic, nothing wrong there. Potential fraud, being investigated. You can't quantify something like that. When he doesn't know, he has to step aside. There's already enough risk in the stock market when you buy the "perfect" company, and it can still go down 10%. He's willing to miss a bit of any upside and wait for a resolution to the story.

Nothing is too big to fail, but UNH is so integrated into the US healthcare system that they are an essential service. Problem is more people are getting utilization in areas that are higher cost. So, their estimates got blown out. Has long owned this. He recommended it for its multiyear consistent earnings. They just reported and are guiding resumption of growth in 2026. Is at a 35% discount to its 3-year forward earnings. He was buying this morning on their earnings call.

It has had issues and it has been a tough year facing several challenges. Owns it in the global equity fund. He is waiting for the conference call tomorrow which should talk about how the issues are being dealt with. They have pulled their guidance on EPS and the new CEO could be putting out a new guidance level. Wait for the base line to grow but there is long term upside.

She averaged down and bought at $273 in May. Stock's been under a lot of pressure. Largest US healthcare manager, with strong vertical integration. Guidance cut, EPS outlook dropped. Under 11x forward PE despite 13-16% long-term target EPS growth. Sees ~25% upside from here.

It could be a long turnaround, though the CEO is the person who can turn it around. You need fortitude to be in this.

Really tough situation. When an insurance company falls on hard times, it's so difficult to analyze. How pervasive are the problems? Historically, quite a strong compounder. Lots of political pressure on insurance reimbursement. Steer clear for now.

Time will tell is they recover or not from the recent slide (shares fell by half). Their medical cost ratios have risen and we'll see if they maintain a higher level. There were fewer medical procedures during Covid, but has since increased, but also has pushed up costs for the insurers. But some issues may be temporary, including Medicare and Medicaid rates.